  |
myfortic® Offers Well-Documented Safety Profile
Adverse events (%) in controlled de novo and maintenance renal studies reported in >20% of patients
| |
de novo Renal
Study |
Maintenance Renal
Study |
| |
myfortic®
1.44 g/day
(n=213) |
MMF
2 g/day
(n=210) |
myfortic®
1.44 g/day
(n=159) |
MMF
2 g/day
(n=163) |
| Anemia |
21.6 |
21.9 |
— |
— |
| Leukopenia |
19.2 |
20.5 |
— |
— |
| Constipation |
38.0 |
39.5 |
— |
— |
| Nausea |
29.1 |
27.1 |
24.5 |
19.0 |
| Diarrhea |
23.5 |
24.8 |
21.4 |
24.5 |
| Vomiting |
23.0 |
20.0 |
— |
— |
| Dyspepsia |
22.5 |
19.0 |
— |
— |
| Urinary tract infection |
29.1 |
33.3 |
— |
— |
| CMV infection |
20.2 |
18.1 |
— |
— |
| Insomnia |
23.5 |
23.8 |
— |
— |
| Postoperative pain |
23.9 |
18.6 |
— |
— |
|
Click here for full prescribing information, which includes contraindications, warnings, precautions, and adverse events.
myfortic: Dosing >>
Click here for complete prescribing information, which includes contraindications, warnings, precautions, and adverse events.
Back to top
|
